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Background: The Philippines is a high TB and multidrug-resistant TB burden country. Although the scale-up of
GeneXpert testing is occurring, the benefits of universal Xpert-Mycobacterium tuberculosis/ rifampicin (MTB/RIF)
testing in inpatients have not been documented.
Methods: Routine GeneXpert testing irrespective of priority criteria for testingwas conductedwithin a prospective
cohort of all adults with known or presumptive TB admitted to a tertiary infectious diseases hospital in Manila.
Study-specific TB diagnosis was decided upon bacteriological results, chest x-ray assessment, if already on anti-
TB treatment (ATT) at admission and a cough duration of ≥2 wk.
Results: Of submitted sputum samples, 87.1% (277/318) had valid acid-fast bacilli (AFB) microscopy and
Xpert® MTB/RIF results. Xpert® MTB/RIF was positive in 97.7% (n = 87/89) of AFB-positive patients and 25.5%
(n = 48/188) of AFB-negative patients. Bacteriological confirmation in smear negative cases not on ATT prior
to admission was 25.2% (34/135). Rifampicin resistance was detected in 26/135 Xpert positive cases (19.3%),
including nine who might not otherwise have been detected, representing a 53% increase in yield.
Conclusion: Universal GeneXpert testing in this setting enhanced the yield of bacterial confirmation, revealing a
high incidence of rifampicin resistance and suggesting a need for further investigations in Xpert-negative/smear-
positive patients who may not have mycobacterial TB.
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Introduction
Diagnosis of TB caused by Mycobacterium tuberculosis (MTB)
remains challenging. Low-sensitivity sputum-smear microscopy
for acid-fast bacilli (AFB) remains the major diagnostic tool
in many resource-limited and high TB burden settings.1,2 The
Xpert® MTB/rifampicin (MTB/RIF) assay is reported to have
89% sensitivity and 99% specificity in detecting adult pul-
monary TB and simultaneously detects resistance to the first-
line drug rifampicin.1,3 Xpert®MTB/RIF increases diagnostic accu-
racy and shortens time to initiate appropriate treatment with
early detection of drug resistance. The WHO endorsed Xpert®
MTB/RIF in 2011 and its large-scale rollout is supported glob-
ally,4 but implementation as a primary diagnostic test remains
limited due to higher upfront costs, logistical challenges and
subsequent increased requirement of multidrug-resistant (MDR)
treatment regimens following identification of rifampicin resis-
tance.5-7 Nonetheless, Xpert®MTB/RIF as the first-line diagnostic
test in place of AFB smearmicroscopy has been shown to be cost-
effective when followed by timely treatment initiation.6,7
Philippines is currently ranked third in the world for TB inci-
dence (554/100 000) and is also a high burden country for MDR-
TB.8 The Philippines introduced Xpert® MTB/RIF in 2011 and
has recently expanded access.9 Based on test availability and
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accessibility, current national testing policies prioritize retreat-
ment cases, contacts of confirmedDR-TB cases, people livingwith
HIV, prisoners, older people, children and, most recently, those
with diabetes.4,10 In some regions, presumptive TB patients with
chest x-rays (CXR) suggestive of TB are now also eligible to be
tested.4,10 Progress and experiences in Xpert® MTB/RIF imple-
mentation have mostly been documented in routine outpatient
programmatic settings.5 We hypothesized that universal Xpert®
MTB/RIF should be implemented in a tertiary hospital setting
where suspected TB patients and those already on anti-TB treat-
ment prior to admission, often with undocumented diagnostic
and treatment histories, are admitted to increase detection rates
of MDR-TB and reduce time to the start of appropriate treatment
regimens. Therefore, we aimed to determine the possible bene-
fits of implementing universal Xpert® MTB/RIF, defined as test-
ing all patients able to produce sputum, in TB ward admissions
with presumptive TB and of those already initiated on an anti-TB
treatment (ATT) regimen in a large tertiary-level infectious dis-
eases hospital in Manila, Philippines. Presumptive and confirmed
TB patients are admitted according to the treating physician’s
assessment of deteriorating clinical condition, or risk of deteri-
oration requiring inpatient care (normally at least supplemental
oxygen and fluids). At the time of the study, non-priority groups
or those already on treatment at the time of admission were not
routinely eligible for Xpert® MTB/RIF.
Materials and methods
A prospective cohort study of inpatients admitted to the TB
ward at San Lazaro Hospital, serving a poor population in Manila
with high TB admission and mortality rates, was conducted as
previously described.11 Patients were recruited from July 2016–
May 2017 and followed up until in-hospital death or discharge.
Research nurses assisted enrolled participants to expectorate
early morning sputum samples. AFB sputum-smear microscopy
(Ziehl Neelsen stain) and Xpert® MTB/RIF (Cepheid, Sunnyvale,
California, USA) testing were conducted on all samples. The most
recent CXR were assessed by two study clinicians to classify
whether they were suggestive of TB and to score severity.12
Symptom history and previous TB history were ascertained by
patient interview. HIV testing was offered to all study partici-
pants, with additional study-specific consent. Hospital admission
and final diagnoses were extracted from clinical notes.
For the purpose of this analysis, study-defined TB comprised:
(1) sputum-smear positive; (2) sputum-smear negative, Xpert®
MTB/RIF positive; (3) already on ATT at admission; (4) cough
≥2 wk and CXR suggestive of TB regardless of sputum results.
Sputum-smear positive, Xpert® MTB/RIF-negative patients were
defined as possible non-mycobacterial TB infection (NTM). Those
with invalid or missing sputum-smear microscopy or Xpert®
MTB/RIF results were excluded from analysis.
Results
Three hundred and eighteen participants who survived the first
48 h of admission provided sputum samples, of whom 87.1%
(n = 277) had both valid AFB microscopy and Xpert® MTB/RIF
results (Figure 1). HIV status was known for 118/277 (42.2%),
with 18/118 (15.3%) being HIV-positive. Xpert® MTB/RIF identi-
fied MTB in 97.7% (n= 87/89) of AFB-positive patients and 25.5%
(n = 48/188) of AFB-negative patients. In all Xpert® MTB/RIF-
positive patients, the prevalence of rifampicin resistance was
19.3% (26/135).
Impacts of universal Xpert® MTB/RIF testing
Figure 1 shows the numbers of patients by smear AFB result
(positive/negative), split by Xpert® MTB/RIF MTB result (posi-
tive/negative), then by ATT initiated prior to admission (yes/no),
then by rifampicin resistance detected by Xpert® MTB/RIF
(yes/no) and finally by TB treatment category (new, relapse or
treatment after loss to follow-up/previous treatment outcome
unknown). The numbers of patients who were HIV-positive and
those already on MDR treatment regimens upon admission are
marked at the final level of TB treatment category. The numbers
and proportions of participants who died during admission are
shown, down to the level of rifampicin resistance detected by
Xpert® MTB/RIF.
Increased yield of bacteriologically confirmed cases of
TB
Of 135 participants who were sputum AFB-negative and not on
ATT prior to admission, 34 (25.2%) were Xpert®MTB/RIF-positive.
Fourteen of these (41.2%) did not have any of the priority crite-
ria of HIV-positive status, aged ≥65 y or a history of previous TB
treatment, and thus would not normally have been tested. This
reduced to 13 participants if previously diagnosed diabetes was
included as a priority criteria, or 11 if HbA1c ≥6.5% at admis-
sion was included as a priority criteria (Table 1). One hundred and
fifty-nine patients (57.8%) had unknown HIV status after declin-
ing testing, of whom 31 had none of the above priority criteria for
testing. Two of these 31 patients were found to have rifampicin
resistance (Table 1). Of 53 participants who were sputum AFB-
negative and already on ATT prior to admission, 14 (26.4.%) were
Xpert® MTB/RIF-positive.
Increased detection of MDR-TB
Five of 113 (4.4%) of newly diagnosed TB patients and 20/160
(12.5%) of TB patients with a history of previous TB treatment
had rifampicin resistance detected by Xpert® MTB/RIF. Of 135
participants who were MTB-positive by Xpert® MTB/RIF, 26 had
rifampicin resistance detected by Xpert® MTB/RIF, of whom only
one was already diagnosed as MDR-TB and 5/26 (19.2%) had
no previous history of TB treatment. Two patients had none of
the priority criteria for Xpert® MTB/RIF testing of positive HIV
status, history of previous TB treatment, aged≥65 y or previously
diagnosed diabetes. An additional case had missing history of
previous TB treatment, which, if included, would have resulted
in 11.5% (3/26) of cases that would otherwise not have been
identified (Table 1). Detailed characteristics of the 26 patients
with rifampicin resistance are available in Supplementary Table
1. Of the 66 patients already on first-line (drug-sensitive [DS]-TB)
ATT at admission, six were identified to have rifampicin resistance
(9.1%), suggesting either failure to identify MDR-TB at treatment
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Figure 1. Bacteriological results by anti-TB treatment at admission, HIV status and TB registration category. *Rif positive+ indeterminate;
[x] Number of HIV positive patients; †[x] 0%Number and percentage of inpatient deaths; [x] Number of patients onMDR treatment at time of admission;
[x] Number of patients with unknown TB registration category; N: New = 114 (41.6%), R: Relapse = 100 (36.5%), T: Treatment after LTFU or previous
treatment outcome unknown = 60 (21.9%) (N = 274); AFB: acid fast bacilli; ATT: anti-TB treatment. Red circles: indicate rifampicin resistant cases not
eligible for GeneXpert testing based upon New TB category, AFB-positive and no other risk criteria (e.g. HIV infection); Orange circles/ellipsoids: indicate
cases of possible Non-Tuberculous Mycobacteria; Blue box: indicates increased number of cases that were bacteriologically confirmed by GeneXpert;
Blue circle: indicates rifampicin resistant cases not eligible for GeneXpert testing at the time of the study (New cases and AFB-negative) unless other
risk factors (e.g. HIV infection); Blue ellipsoid: indicates bacteriological confirmation in those already on Anti-TB treatment previous to admission;
Green box: indicates cases needing further investigation of differential diagnoses and culture if strongly suspicious of TB.
Table 1. Characteristics used to determine priority for Xpert® MTB/RIF testing
Priority testing criteria
AFB-negative, Xpert®
MTB-positive
patients (n = 34)
Xpert®
Rifampicin-resistant
patients
(n = 26)
Retreatment 16 (64%) 20 (77%)
MDR-TB contact No data No data
HIV-positive, or pre-admission HIV diagnosis 1 (25 refused) (4%) 4 (9 refused) (15%)
Prisoner 0 (0%) 0 (0%)
Age ≥65 y 5 (15%) 1 (4%)
Diabetes (pre-admission diagnosis) 3 (9%) 2 (8%)
Diabetes (previous diagnosis or HbA1c ≥6.5% at admission) 7 (21%) 5 (19%)
No priority testing criteria 11 (32%) 3 (12%)*
Already on DS-ATT prior to admission 0 (0%) 6 (1 on MDR
regimen)
Bold indicates cases which would have been missed if testing was based on above priority criteria only.
AFB: acid-fast bacilli; DS-ATT: drug-sensitive anti-TB treatment (initiated before the current admission); HbA1c: glycated hemoglobin.
*n = 2 new TB cases with no other priority criteria plus 1 with missing information on previous history of TB treatment.
start, or development of drug resistance on treatment. All of
these had one or more priority criteria (four with a previous
history of TB treatment, three with a previous HIV diagnosis). In
a scenario of not testing those already started on first-line ATT or
new TB cases without other priority criteria, additional cases of
rifampicin resistance detected by universal testing in this study
include two new TB registration cases with negative or unknown
HIV status (refused), one HIV-negative patient with an unknown
TB registration history, plus six cases on first-line ATT prior to
admission. Together, these represent a 53% increase in yield in
identifying rifampicin resistance using universal Xpert® MTB/RIF
testing.
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Identification of possible NTM infection
Two participants were AFB-positive (with grade+++ and++++)
but GeneXpert-negative. Both had a previous history of TB treat-
ment and one was on ATT at admission.
Identification of probable non-TB for further
investigation
Approximately half of all participants were AFB-negative and
GeneXpert-negative, of whom 72.1% (n = 101/140) were not
on ATT prior to admission. Of those 101, only 57 (56.4%) met
the study criteria for TB (a cough of duration ≥2 wk and CXR
suggestive of TB). Forty-three of these patients had a history of
previous TB, of whom 30 were relapse, 11 treatment after loss
to follow-up and two previous treatment outcome unknown.
Of the remaining 44 patients, one was clinically diagnosed with
extra-pulmonary TB.
Inpatient mortality
There were 49 inpatient deaths among the 277 individuals
included in this analysis (17.8%). The distribution of inpatient
deaths by the different diagnostic groups and by treatment sta-
tus at admission is shown in Figure 1. There was some evidence
of increased risk of inpatient death for those who were already
on ATT prior to admission (8/82 [25.0%] vs 31/205 [15.1%]; OR =
1.87, 95% CI 0.97 to 3.61, p= 0.061), but no evidence of an effect
of rifampicin resistance, with six deaths in the 27 with rifampicin
resistance (including one indeterminate result; 22.2%) and 26
deaths in the 114 without rifampicin resistance detected (22.6%)
or 43 deaths in 250 (17.2%, p = 0.52) compared with everyone
without rifampicin resistance.
Final hospital-defined diagnosis vs study-defined TB
Thirty-six of 268 patients (13.4%) in this analysis who had a
recorded hospital diagnosis of TB did not have TB according to
our study definition. Of those 36 patients, two were possible NTM
infections and five did not have a CXR suggestive of TB but only a
cough of 2 wk.
Discussion
The 25% increased rate of bacteriological confirmation in spu-
tumAFB-negative patients using Xpert®MTB/RIF is similar to that
reported elsewhere.1 The prevalence of rifampicin resistance in
new TB diagnoses in this setting (4.4%) was higher compared
with the national estimate of 1.7% (95% CI 1.1 to 2.5%) of
rifampicin resistance or rifampicin and isoniazid resistance in new
cases,8 or compared with the 2012 National Tuberculosis Drug
Resistance Survey of 2.43% (95% CI 1.75 to 3.37%) for rifampicin
resistance detected by phenotypic drug sensitivity testing.13 Uni-
versal Xpert®MTB/RIF testing detected 135 cases ofMTB and two
cases of rifampicin resistance in patients who otherwise would
not have been detected if applying the current priority criteria for
testing. Six cases of rifampicin resistance in patients on first-line
(DS-TB) ATT were also detected at admission.
In some regions Xpert® MTB/RIF priority testing has been
extended to people who are AFB-negative but with a CXR sug-
gestive of TB.1,4,10 In this study population this would not
have resulted in any additional rifampicin resistant cases being
detected, as the two patients who were rifampicin resistant-
negative for AFB each had other criteira for testing (i.e. a history
of previous TB treatment and known HIV-positive status).
Universal Xpert® MTB/RIF testing also assisted in identifying
a large group of admissions unlikely to have TB but who were
mostly treated as clinical TB, highlighting potential overdiagno-
sis1,10 and exposure to unnecessary toxic TB treatments.1,10,14
NTM accounted for 3.2% of specimens collected and 17.2%
of smear-positive Xpert-negative specimens in the Philippines
2016 TB prevalence survey.15 Although sputum handling errors
could not be ruled out, it seems likely that the two smear-positive
Xpert-negative cases in this study were NTM infections. In set-
tings such as this, where bacterial culture is not routinely avail-
able, Xpert in combination with slide microscopy may be useful
in selecting patients for culture in the diagnosis of NTM.
The limitations of this study include a lack of information
regarding MDR-TB contact, which is a priority criteria for Xpert®
MTB/RIF testing, no available culture confirmation of TB or NTM, or
drug sensitivity testing. Also, we were not able to compare time
to starting appropriate ATT regimens as a result of implement-
ing universal Xpert® MTM/RIF testing. The basis of previous TB
diagnoses for patients on ATT at admission could not be ascer-
tained for the majority of cases due to a missing National TB Pro-
gram (NTP) treatment card or traceable NTP number. Although
wedid attempt to trace TB treatment outcomes for patients post-
discharge, due to the relatively high rate of loss to follow-up,11 we
have not attempted to include this outcome here.
The high prevalence of rifampicin resistance in this setting
supports the use of universal Xpert® MTB/RIF. Additionally, for
individuals already on first-line ATT requiring hospitalization, high
clinical suspicion of drug resistance is justified and supports the
use of universal Xpert® MTB/RIF in inpatient admissions. This is
particularly the case when the basis of TB diagnosis and treat-
ment adherence are unknown. Despite national Xpert® MTB/RIF
guidelines, availability cannot be assumed in settings with unreg-
ulated private healthcare providers and poor mobile urban pop-
ulations. Unselective Xpert® MTB/RIF testing in these kinds of
settings may be cost-effective for TB programs due to reduced
delays to starting appropriate treatment and reductions in TB
mortality and transmission.7
Supplementary data
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